Vpr, an accessory gene of HIV-1, induces cell cycle abnormality with accumulation at G2/M phase and increased ploidy. Since abnormality of mitotic checkpoint control provides a molecular basis of genomic instability, we studied the effects of Vpr on genetic integrity using a stable clone, named MIT-23, in which Vpr expression is controlled by the tetracycline-responsive promoter. cdc2 activity is down-regulated with a nonphosphorylated inactive form of CDC25C (17). It was recently reported that the viral replication increased more than twofold in the cells arrested by Vpr (18), which could explain why the virus with wild-type (WT) Vpr would have a replication advantage in vivo (18, 19) .
crucial for productive infection to macrophages (6, 7) . Recently, several groups have reported that the Vpr of HIV-1 induces cell cycle abnormality (see review, ref 8) , causing cell accumulation at G2/M phase and increased ploidy. Such a biological function of Vpr is conserved in primate lentiviruses (9) and in a variety of cells including mammalian cells (10 -13) , yeast (14, 15) , and bacteria (16) . In Vprexpressing cells, cyclin B-dependent p34 cdc2 activity is down-regulated with a nonphosphorylated inactive form of CDC25C (17) . It was recently reported that the viral replication increased more than twofold in the cells arrested by Vpr (18) , which could explain why the virus with wild-type (WT) Vpr would have a replication advantage in vivo (18, 19) .
It is now well accepted that cell cycle abnormality would serve as a molecular basis for genomic instability in tumors (20) . One of the tumor suppressor genes, p53, causes cell cycle arrest at G1/S phase when cells are treated with DNA damaging agents (21) , the dysfunction of which induces genomic instability such as gene amplification (22) (23) (24) . Recently, it was reported that p53 was also related to mitotic checkpoint control (25) . Abrogation of mitotic checkpoint control induces genomic instability (25) (26) (27) (28) (29) . For instance, a mutation of the human BUB1, a homologue to the yeast gene regulating mitotic spindle checkpoint control (28) , was detected in human colon 1 Correspondence: Department of Intractable Diseases International Medical Center of Japan, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan. E-mail: zakay@ri.imcj.go.jp. 2 Abbreviations: CCB, cytochalasin B; DAPI, 4,6-diamidino-2-phenylindole; DOX, doxycycline; FACS, fluorescein-activated cell sorter; HIV-1, human immunodeficiency virus type 1; MIN, micronuclei; PBS, phosphate-buffered saline; PBST, PBS supplemented with 0.02% Tween 20; PI, propidium iodide.
tumors (29) . The expression of the mutated human BUB1 gene resulted in the abrogation of M phase checkpoint control (29) .
Tumors such as B cell lymphomas and Kaposi's sarcomas are frequently observed in AIDS patients (30, 31) . Although tumor development in the AIDS patients has been considered as a result of the compromised immunosurveillance mechanism , it was recently pointed out that HIV itself was actively involved in tumorigenesis (35, 36) . The molecular mechanism of the AIDS-related oncogenesis remains unclear, but it is tempting to speculate that Vpr, which induces perturbation of cell cycle, works as one of the causative factors in tumor development.
We present evidence here suggesting that Vpr induces a high frequency of micronuclei (MIN) formation, a hallmark of aneuploidy (37) (38) (39) (40) . Data suggest that Vpr serves an important role in the development of AIDS-related tumors.
MATERIALS AND METHODS

Plasmids and reagents
Plasmids for the reverse-tet system (41) were from Dr. Bujard (Heidelberg University, Germany). A plasmid, pUHD172-1neo containing a neomycin-resistant gene as a selective marker, encodes a tet-responsive trans-activator, the activity of which is switched on by addition of doxycycline (DOX) (Sigma, St. Louis, Mo.). The plasmid with a tet-responsive DNA element, pUHG16-3 (40) , which was inserted with a hygromycin-resistant gene, was named pTO. An effector plasmid, pTO/Vpr, was constructed by ligating a BamHI fragment of Vpr gene, which was excised from pBABE-vpr (10) to the same sites of pTO. The Vpr gene was originally cloned from HIV-1 NL . The sense orientation of the constructs was confirmed by restriction mapping.
Deletion mutants of Vpr, ⌬C2, ⌬C5, and ⌬C12, which lacked carboxy-terminal 2, 5, and 12 amino acids, respectively, were generated by polymerase chain reaction using Vent polymerase (Gibco BRL, Grand Island, N.Y.) by using WT Vpr DNA fragment as a template. An oligonucleotide, 5Ј-ATCGATGGAACAAGCCCCAGAA-3Ј, was used as a common forward primer and 5Ј-TTAACTGGCTCCATTTCT-3Ј, 5Ј-TCAATTTCTTGTTCTCCT-3Ј, and 5Ј-TTAAATAAT-GC-CTATTCT-3Ј were used as reverse primers for obtaining C2, C5, and C12, respectively. Each clone was first ligated to a TA cloning vector (Invitrogen, San Diego, Calif.). To make ⌬C18, WT Vpr DNA was digested with SalI first, end-filled with Klenow fragment, then ligated with XbaI linker (5Ј-CTCTA-GAG-3Ј, Promega), which generated an in-frame stop codon around the carboxyl end of LR domain (42, 43) . Each mutant was sequenced and the deduced amino acids were confirmed (see Fig. 4A ); then the inserts were ligated to an expression vector, pBabepuro.
Establishment of MIT-23
Human fibrosarcoma cell line HT1080 was obtained from the Health Science Research Resources Bank ( JCRB9113) of Japan. Cells were maintained in Dulbecco's modified Eagle medium (Nissui, Tokyo, Japan) supplemented with 10% heat-inactivated fetal calf serum (BioWhittaker, Walkersville, Md.) and 2 mM glutamine (Wako, Osaka, Japan). HT1080 was known as a pseudodiploid cell line with apparent 46XY, as described in the ATCC catalogue. Cells transfected with pUHD172-1neo by the reported method (44) were selected with 400 g/ml of G418 (Wako), then each clone was checked for the inducibility of the tet-regulated trans-activator function using pUHC13-3 containing luciferase gene (41) . RTC-12, which showed the highest fold increase of luciferase activity induced by DOX (5 /ml), was further introduced by pTO/Vpr. After the second transfection, cells were cultured in the presence of G418 and hygromycin (25 g/ml) (Wako). Fifty-five clones with resistance to both drugs were picked up and tested for cell cycle abnormality with 5 g/ml of DOX. Fourteen of these 55 clones were chosen as candidates for DOX-inducible cell cycle abnormality, one of which was picked up as the best clone and named MIT-23 (multinuclear cell induced by tetracycline). As a control clone, ⌬VPR, which was introduced with the plasmids containing the same components except for Vpr gene, was obtained. In some experiments, ⌬VPR-5 and -6, which were subclones from ⌬VPR cells, were used.
FACS analysis of cell cycle and MPM-2-positive cells at M phase
Cell cycle analysis was performed by the method reported (45) . Propidium iodide (PI) (Sigma) at the concentration of 50 g/ml was used for DNA staining. Cells at M phase were stained with MPM-2 antibody (DAKO, Bucks, U.K.) by the method described (28, 46) . Cells were first treated by a double thymidine block, then further cultured for 12 h in the presence of 0.2 g/ml nocodazole (Sigma). The first antibody with 200-fold dilution was incubated for 1 h at 37°C in phosphate-buffered saline (PBS) supplemented with 0.02% Tween 20 (PBST) added to 10% normal goat serum. An FITC-conjugated goat anti-mouse IgG was used as a second antibody. After washing with PBST several times, DNA was stained with 50 g/ml PI, then 2-dimensional fluoresceinactivated cell sorter (FACS) analysis (Beckton Dickinson, N.J.) was carried out.
Histone H1 kinase activity
Histone H1 kinase activity was measured according to the method reported (47) . Cells were treated with 0.2 g/ml of nocodazole for 24 h, then cell extracts of 100 g protein were immunoprecipitated using a polyclonal antibody to carboxy-terminal amino acids of human CDC2. The precipitates were further incubated in 10 l of a buffer containing 20 mM Hepes-NaCl (pH 7.5), 15 mM EGTA, 20 mM MgCl 2 , 1 mM dithiothreitol, 1 g of histone H1 (Boehringer Mannheim, Mannheim, Germany), and 50 M ␥-32 P-ATP (1000 -2000 cpm/pmol) (Amersham, Arlington Heights, Ill.) for 10 min at 30°C. Each sample was mixed with 20 l of 3ϫ sodium dodecyl sulfate (SDS) sample buffer for terminating the reaction. It was then boiled and applied to SDS-polyacrylamide gel electrophoresis. After electrophoresis, the signal of the phosphorylated histone was exposed to an X-ray film and the intensity of each band was measured.
Preparation of monoclonal antibody against Vpr and immunostaining
clonal antibody provided by the NIH AIDS Research and Reference Reagent Program (Cat. No. 3951) confirmed that the expressed protein is Vpr. After partial purification using hydroxyapatite column chromatography (Seikagaku Kogyo, Tokyo, Japan), about 100 g of the recombinant protein was used for a single immunization. For immunostaining, cells were fixed in 4% paraformaldehyde in PBS, followed by permeabilization in 0.2% Triton X-100. Blocking was performed using PBST with 10% normal goat serum. After washing with PBST, the fixed cells were incubated with one of three antibodies, clones 2A6, 1A2, and 3B4, all of which were IgM subclass, for 1 h at 37°C. For detecting the centromeric component, anti-kinetochore monoclonal antibody (COSMO BIO, Tokyo, Japan) was used. FITC-conjugated anti-mouse IgA, G, and M (Zymed Laboratories, San Francisco, Calif.) were used as a second antibody. DNA was stained with PI at the final concentration of 1 g/m or 50 ng/ml of 4,6-diamidino-2-phenylindole (DAPI) (Sigma). Stained cells were examined in an antifade solution (KPL, Gaithersburg, Md.) using a fluorescence microscope (Olympus, Tokyo, Japan) equipped with a Sensys CCD camera (Photometrics, Tucson, Ariz.). Image analysis was carried out by IP lab. spectrum (Scanalytics, Fairfax, Va.). For checking the specificity of the antibody produced by 2A6 clone, about 10 g Vpr protein that was purified by the BIOCAD system (PerSeptive Biosystems, Framingham, Mass.) was added during incubation of the first antibody.
Karyotype analysis
Karyotype analysis was carried out by Biomedical Laboratories Inc. (Japan) based on the conventional method (48) . Chromosomes were stained with Giemsa solution and examined by a microscope. Twenty to 30 metaphase spreads were examined in each sample.
RESULTS
We first established MIT-23 in which Vpr expression was regulated by DOX addition (see Materials and Methods).
In MIT-23 cells Vpr mRNA as well as its protein expression was controlled by DOX addition. Figure  1A shows that the transcription of Vpr mRNA was quickly induced within 6 h after DOX addition (Fig.  1A, lane 3) and reached a maximum level in 24 h (Fig. 1A, lanes 5 and 6) . On the other hand, DOX removal diminished Vpr mRNA in 12 h (Fig. 1A, lane  9) . Then, Vpr expression was mostly abolished in 48 h after DOX removal (Fig. 1A, lane 12) . Expression of Vpr protein was induced by DOX treatment, as shown in Fig. 1B The induction of H1 kinase activity was inhibited by Vpr expression (Fig. 2D) , as reported by several groups (10, 13, 17) . Although an increase of H1 kinase activity after nocodazole treatment was observed on day 1 in Vpr-expressing MIT-23 cells, this induction was gradually reduced on day 3 and day 5 (indicated by triangles in the upper panel of Fig. 2D ), and on day 7 it was attenuated to less than half that of the control cells ( These data suggest that Vpr induces cell cycle retardation with the cellular accumulation at G2/M phase and hyperploidy, resulting in the decreased H1 kinase activity.
In MIT-23 cells, multinuclear cell formation (multinucleation) was observed by Vpr expression. A typical morphology of multinucleated cells stained with PI is shown in Fig. 3A . More than 20% of cells became multinuclear in 2 days after Vpr expression; on day 10 after Vpr expression, more than 35% of the cells (22% for binuclear cells and 15% for cells with more than 3 nuclei) were multinuclear, as summarized in Table 1 . We also observed mononuclear cells with large nuclei and possibly increased DNA content; some are also shown in Fig. 3A . By contrast, ⌬VPR and MIT-23 cells without Vpr expres-sion did not show any induction of multinuclear cell formation (data not shown). MIT-23 cells, even when small number of cells were plated, became multinuclear cells by Vpr expression, suggesting that multinucleation by Vpr was not due to cell fusion (50, 51) . Figure 3A also shows the presence of MIN, which were resistant to RNase treatment (data not shown). We characterized the relation between multinucleation and MIN formation. The results of an analysis of cells with Vpr expression for 5 days are summarized in Table 2 . The population of multinuclear cells in MIT-23 cells without Vpr expression was only 1.7%, a quarter of which were MIN positive, making the incidence of the MINpositive multinuclear cells in the total population 0.4%. By Vpr expression, the incidence of multinuclear cells increased to 33%, 77% of which were MIN positive. Thus, the incidence of multinuclear cells with MIN in the total population was calculated as 25%. On the other hand, in one of two independent control clones, ⌬VPR-6, the incidence of multinuclear cells with MIN in the total population was 0.5%. In another clone-⌬VPR-5-it was not detected. When the incidence of MIN formation was normalized by the incidence of ⌬VPR-6 as 1, the increase of Vpr-induced MIN formation was 50-fold greater.
To know whether MIN formation is specifically induced by Vpr or simply due to multinucleation of the cells, we compared the incidence of MIN formation in cytochalasin B (CCB) -treated MIT-23 cells Table 3 . By CCB treatment, 60% of MIT-23 cells became multinuclear (90% binuclear) and 3.3% of these multinuclear cells were MIN positive. The incidence of multinuclear cells with MIN induced by CCB treatment was calculated as 2.0%. On the other hand, the incidence of multinuclear cells with MIN induced by Vpr was 8.4%, indicating that the incidence of MIN formation in Vpr-induced multinuclear cells was more than fourfold higher than in CCB-induced multinuclear cells. These observations suggest that MIN formation is not simply because of multinucleation, but that Vpr actively induced MIN formation.
It is important to know whether HIV infection itself induces MIN. To answer this question, MAGI cells, a HeLa cell derivative that expresses the CD4 containing, HIV-LTR-driven LacZ gene (53), were infected with WT HIV (54), then the generation of MIN formation was examined. As shown in Fig. 3B (left panel), HIV-infected cells were identified by X-gal staining. DAPI staining then detected MIN formation in these cells (right panel), and 18% of HIV-infected cells were positive for MIN formation. On the other hand, only 3% of ␤-galactosidasenegative cells contained MIN, indicating that HIV infection itself induced a sixfold increase in MIN formation.
Next we determined the functional domain of Vpr, which is necessary for inducing multinucleation and/or MIN formation. Since it has been reported that the carboxy-terminal region of Vpr is important for cell cycle abnormality (12, 43) , deletion mutants lacking carboxyl amino acids (Fig. 4A) were generated and expressed in HT1080. After about 10 days of selection with puromycin, cell cycle abnormality was analyzed.
Results representative of three independent experiments are shown (Fig. 4B, C) . Figure 4B shows histograms of DNA content of each transfectant and Fig 4C represents the relative increase of cell number at G2/M phase and 8N. The mutants of ⌬C2, ⌬C5, and ⌬C12, which lacked carboxy-terminal 2, 5, and 12 amino acids, respectively, could induce both G2/M accumulation and hyperploidization, as shown in Fig. 4B (panels 3-5) . On the other hand, the mutant of ⌬C18 did not show any changes of cell cycle (panel 6). MIN formation was also studied in these transfectants and we observed that it was increased in all mutants except for C18. In Table 4 , the results of G2/M arrest, multinucleation, and MIN formation are summarized. These data indicate that Vpr-induced MIN formation correlates well to the activity of multinucleation as well as G2/M arrest.
Possible 'asynchronous cytokinesis' after abolishment of Vpr expression
Based on the observation of Vpr-induced multinucleation, cell cycles seemed to be halted at cytokinesis. We studied the result after DOX deprivation. Multinuclear cells started to undergo cytokinesis after DOX removal. Typical morphology is shown in Fig. 5A (panel 1) . From a giant multinuclear cell, many nuclei seemed to be coming out at the same time, as indicated by arrowheads. Figure 5A ( Fig. 5B (nuclei just emerging from the cell and MIN are indicated by arrows and arrowheads, respectively). Such an observation strongly suggested that aneuploidy would be induced by transient Vpr expression. To clarify this point, we studied the effects of transient expression of Vpr on chromosome integrity. As the experimental protocol shows in Fig. 6A , the addition of DOX, followed by its removal, was repeated three times and then the cell cycle pattern after each procedure was examined. The populations corresponding to '4N' and '8N' gradually increased after each cycle of transient Vpr expression ( Fig. 6B: 59 , 68, and 83%, as shown in panels b, d, f). MIT-23␥ cells, which had about 80% of cells located in 4N and 8N, were further cultured without the presence of DOX. The ploidy change is shown in Fig. 7A . The major 4N peak became more prominent and the 2N peak became very small (panels 1-5). On day 252, the population with 2N disappeared (panel 6). Most MIT-23␥ cells contained more than 4N DNA content. In MIT-23␥ cells Vpr mRNA was not expressed, as examined by Northern blot analysis (data not shown). Using a monoclonal antibody, MPM-2, which recognizes phosphorylated proteins specifically present at M phase (46) , the kinetics of cell cycle was studied in MIT-23␥ cells (Fig. 7B ). Cells were first synchronized at early S phase by double thymidine block, then released in the presence of nocodazole. MIT-23 cells just after the thymidine block contained a few MPM-2-positive cells (Fig. 7B, panel  1) . After 12 h treatment with nocodazole, the increase of MPM-2-positive cells was observed in the region corresponding to cells composed of 4N DNA (Fig. 7B, 'R2' in the panel 3) . The population of MPM-2-positive cells was 9.0%. On the other hand, two kinds of MPM-2-positive populations were recognized in the MIT-23␥ cells (R2 and R3 in panel 7 of Fig. 7B ). One population corresponded to an apparent DNA content of 4N (R2 in panel 7) and the other to a possible 8N (R3).
In two other independent experiments, we confirmed the reproducibility of the Vpr-induced ploidy change in MIT-23 cells, whereas ⌬VPR cells showed no changes in ploidy from the same DOX treatment (Fig. 7A, panels 7 and 8) . In addition to MIT-23␥ cells, MIT-23/409, which was cultured with continuous expression of Vpr for 6 months, also became hyperploid cells (data not shown).
Karyotype analysis of MIT-23␥ cells detected that all of the 30 metaphase spreads studied had abnormal numbers of chromosomes. The representative karyotypes are shown in Fig. 8 (panels 1 and 2) and the results were summarized in Table 5 . In addition, MIT-23/409 cells were also aneuploid (Fig. 8, panel  3 and Table 5 ). Before treatment of DOX, MIT-23 cells showed pseudodiploid, as did HT1080 (Fig. 8,  panel 4 and Table 5 ). We confirmed that there were no changes in karyotype of ⌬VPR cells exposed to DOX by the same protocol as MIT-23␥ cells (Fig. 8 , panels 5 and 6, and Table 5 ), suggesting that aneuploidy was caused by Vpr.
DISCUSSION
Vpr-specific cell cycle abnormality in MIT-23 cells
In the present study, we established a cell line in which Vpr expression was tightly regulated by DOX treatment. Cell cycle abnormality was never observed in DOX-treated control ⌬VPR cells. Furthermore, we checked cell cycle abnormality, using more than 100 clones that were transfected with the same plasmids in which only the Vpr fragment was replaced with other DNAs, such as SLAP (src-like adapter protein) cDNAs (55) . There were no clones except for Vpr transfectants, which showed cell cycle abnormality in response to DOX treatment. In addition to MIT-23 cells, we observed essentially the same phenotype in other clones; the result of one (b4-30) is presented in Fig. 2A (panels 5 and 6). Southern blot analysis on the DNAs extracted from clones gave different hybridization pattern to the Vpr probe (data not shown), indicating that the phenotype observed in the present study is not due to the effects of integration sites of transfected Vpr gene, but is strictly Vpr specific. 1-6 ). ⌬VPR cells treated with DOX three times were also analyzed (panels 7 and 8). B) MPM-2 staining on MIT-23␥. MIT-23 and MIT-23␥ were first treated with double thymidine block (2.5 mM) (panels 1, 2, 5, and 6), then transferred to the culture with the presence of nocodazole (2.5 g/ml). After 12 h, cells were harvested (panels 3, 4, 7, and 8) and subjected to analysis. Cell cycle analysis (panels 2, 4, 6, and 8) and 2-dimensional analysis of DNA content and MPM-2 (panels 1, 3, 5, and 7) are shown. The population of R2 region in panel 3 was 9%. The populations corresponding to R2 and R3 region in panel 7 were 3% and 15%, respectively.
Multinucleation and G2/M arrest induced by Vpr
In MIT-23 cells, Vpr induced multinucleation as well as G2/M arrest. It was reported that Vpr induced hyperploidy in single nuclei when it was expressed in Jurkat cells (13) . There are, however, several reports showing the formation of multinuclear giant cells as the phenotype of Vpr activity. In these reports adherent cells such as rhabdomyosarcoma cells (56), osteosarcoma cells (10) , and HeLa cells (43) were used, suggesting that Vpr-induced multinucleation is dependent on cell types. Another possible, more likely explanation is based on our experience in the present study, which is that multinucleation takes more time than G2/M arrest. In HT1080 cells, G2/M accumulation was observed a few days after transfection of Vpr gene, but it takes at least 7 days for multinucleation (M. Shimura, unpublished results).
To date, all experiments on Vpr have been performed based on transient expression assays, and Vpr-induced multinucleation may have passed unnoticed in some cases. Apoptosis is not a major biological phenomenon in MIT-23 cells, although occasionally it is induced by Vpr (57).
Vpr-induced MIN formation and aneuploidy
The incidence of MIN in Vpr-expressing cells was more than 50-fold higher than in control cells (Table  2) . Furthermore, Vpr induced a fourfold higher incidence of MIN formation than CCB, an inhibitor of the function of spindle fibers. Because the incidence of CCB-induced multinucleation was twice as much as that induced by Vpr (Table 3) , we suggest that MIN formation induced by Vpr is not due to the secondary effects of multinucleation, but by active function of Vpr. MIN formation was observed in other cell lines such as V79, HeLa, and 293 cells. In V79 cells, for example, an 11-fold higher incidence of MIN formation was found in Vpr-expressing multinuclear cells than in Vpr-negative cells (data not shown). It is noteworthy that HIV infection itself caused MIN formation, as presented in Fig. 2B . These data suggest that Vpr generally induces MIN formation. MIN formation has been considered a hallmark of aneuploidy and is used for assessing mutagenicity of the test compounds (37) (38) (39) (40) . On the other hand, we observed MIN remaining in the cytoplasm during asynchronous cytokinesis (Fig. 5A) , which suggests that the transient Vpr expression easily induced genetic unbalance in parental and daughter cells. As a consistent result, MIT-23 cells turned out to be aneuploid after transient Vpr expression, as shown in Fig. 8 and Table 5 . Furthermore, we found that Vpr induced chromosome breaks, resulting in a high incidence of gene amplification (M. Shimura, unpublished results). An apparent asymptomatic phase has been pointed out (58) in the natural history of HIV infection. Even during such a period, virus is actively produced (59 -61) . Reports that Vpr is present in the AIDS patients' sera (62, 63) and that exogenously added Vpr can enhance viral production of the cells with latent infection (62, 63) suggest that Vpr would be distributed in the whole body of the AIDS patients. Many cells are susceptible to repeated or continuous exposure of Vpr affecting genetic integrity. It is reasonable to speculate that Vpr serves as a molecular basis of malignancies in AIDS patients.
Mechanism of Vpr-induced cell cycle perturbation
In the present study, we determined the functional domain of Vpr that induced MIN formation, G2/M arrest, and multinucleation. Deletion mutants lacking carboxy-terminal 12 amino acids could induce all of these phenotypes ( Fig. 4B, C ; Table 4 ). On the other hand, the mutant without carboxyl 18 amino acids did not show such an abnormality, suggesting that at least the carboxyl terminus of Vpr plays an important role for these phenotypes.
It has been reported that Tax of HTLV-1 also induced MIN formation (64, 65) . In an important finding, Tax oncoprotein was recently shown to induce multinucleation by interfering with the interaction of MAD1 and MAD2 (26) , mammalian homologues to yeast genes that are involved in mitotic checkpoint control (26, 66) . The molecular mechanism of Tax-induced genomic instability was well studied using various mutants. The functional domain inducing MIN formation was shown to be present primarily in its carboxy-terminal region (65) , whereas the activity of multinucleation and MAD1 binding was present in the amino half of the protein (26) , suggesting that MIN formation and multinucleation were perhaps regulated by different mechanisms. It remains to be clarified whether Vpr induces cell cycle abnormality based on the same molecular mechanism as Tax. Tax-induced multinucleation was enhanced by the addition of nocodazole, suggesting that the functions of Tax and nocodazole are on the same pathway of G2/M checkpoint control (26) . To the contrary, we observed that Vpr-induced multinucleation was reduced by nocodazole from 26% to 18% of the population (M. Shimura, unpublished data). In addition, immunostaining of Vpr indicated that it was not present in the midbody (Fig.  1B, panel 4 , indicated by an arrow), where MAD1 had been reported to be localized (26) . The staining pattern of MAD2 (66) , which was reported to localize in centrosomes, is also different from that of Vpr (M. Shimura, unpublished results). It is likely that the mechanisms of multinucleation by Vpr and Tax are different.
We now hypothesize that there are at least two molecular mechanisms of Vpr-induced G2/M arrest, one occurring in cytoplasm and the other in the nucleus. The LR domain of Vpr (42, 43, 67) was reported to have 60% identity with a product of Sac1p, a yeast gene regulating the cytoskeletal function (68) . Vpr, even as a whole protein, had 30% identical amino acids with 45% similarity to SAC1P (68) . Actually, Vpr was reported to induce actin disruption (69) . Furthermore, even Vpr mutants that lacked the property of nuclear translocation could induce G2/M arrest (43) . This information supports the idea that Vpr impairs cytoskeletal proteins as well as those present in cytoplasm, which also include mitochondrial proteins (14) . Another possibility is that G2/M arrest could be induced by the event evoked in nuclei. We observed a high frequency of Vpr-induced chromosome breaks in main nuclei and in MIN (M. Shimura, unpublished results). Vprinduced DNA damages, in turn, arrest cells at G2/M phase, as reported in ␥-irradiated cells (70, 71) . G2/M arrest in Vpr-expressing cells may be caused by more than a single molecular event.
Currently we are characterizing cellular proteins that interact with Vpr by comparing the peptide pattern detected in the transfectants expressing WT Vpr and mutant Vpr that fail to induce cell cycle abnormality. Studying the molecular mechanism of Vpr-induced cell cycle perturbation may uncover a novel machinery of spindle checkpoint control.
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